Remove Containment Remove Immune Response Remove Production
article thumbnail

ESMO 2022: the evolution of TIL therapy – a highly promising approach

Pharmaceutical Technology

As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Numerous academic and pharma-led studies have investigated the efficacy of TILs in the melanoma setting, with response rates ranging from very low to 50%.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. 1 variant as well as the original 2020 strain.”.

article thumbnail

World Psoriasis Day 2024: New Treatments and Research Trends

XTalks

AX-158 offers a new class of therapy, by targeting immune responses without causing immunosuppression, making it a potentially safer option for long-term treatment, with results expected by the end of 2024. The Psoriasis Diet Diet has long been an area of research as a potential factor in managing psoriasis.

Research 105
article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. The regulations regarding BLAs for therapeutic biological products are included in 21 CFR parts 600 , 601 , and 610.

article thumbnail

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

pharmaphorum

The vaccine, codenamed BNT162b5, codes for “enhanced” prefusion spike proteins from the original wild-type strain of the virus and the Omicron variant that are designed to increase “the magnitude and breadth of the immune response.” Clinical data show strong neutralising antibody responses against Omicron BA.1,

Protein 122
article thumbnail

Polyrizon IPO Strengthens Momentum in Non-Invasive Drug Delivery Solutions

XTalks

per unit, included 958,903 units, each containing one ordinary share and three warrants to purchase additional shares at an exercise price of $4.38 Proceeds from the IPO will fund preclinical and clinical development for Polyrizon’s innovative hydrogel product candidates, supporting further research and development (R&D).